The kinetics of plasma homocysteine were determined in 13 healthy subjects after peroral administration and in one person after intravenous injection. Various forms of homocysteine completely dissolved in an aqueous solution were rapidly absorbed after peroral administration, and the bioavailability was estimated to be 0.53. The volume of distributionwas 0.66 L/kg. The area under the plasma concentration curve (AUCQ h) was proportional to the administered dose (33.5-134 moI/kg body wt), and showed small interindividualvariations. Plasma homocysteine showed first-order elimination kinetics for at least 6 h. The half-life (t112) was 223 ± 45 mm, and there was a significant correlation between t112values determined on two different occasions in the same individual. The transient hyperhomocysteinemia was associated with an increase in plasma methionine, which probably reflects intracellular remethylation of homocysteine. Less than 2% of the administered homocysteine dose was recovered in the urine. These findings may form the basis for future studies on the regulation of plasma homocysteine in health and disease, and should motivate the evaluation of a homocysteine loading test as a diagnostic tool. The plasma homocysteine concentration in fasting subjects heterozygous for cystathiomne fl-synthase deficiency is usually within the normal range. To identify such subjects, the methionine loading test has been used in several clinical studies (6, 7). The test is based on peroral administration of a standard dose of methionine and measurement of the plasma homocysteine concentration 4-6 h after intake. The test improved the discrimination of heterozygotes from controls in some studies, but discontinuous segregation between the two groups was not obtained (8). This may reflect the interindividual variation in response to a standard methionine load (9), which may be due to, among other factors (9), the fact that plasma homocysteine is a function of both homocysteine formation and metabolism.
methionine as a product of transmethylation. Intracellular homocysteine is either salvaged to methionine or degraded to cysteine. The former reaction is in most tissues catalyzed by the enzyme 5-methyltetrahydrofolate-homocysteine S-methyltransferase (methionine synthase; EC 2.1.1.13), which requires 5-methyltetrahydrofolate as methyl donor and cobsilamun as cofactor. The first step The plasma homocysteine concentration in fasting subjects heterozygous for cystathiomne fl-synthase deficiency is usually within the normal range. To identify such subjects, the methionine loading test has been used in several clinical studies (6, 7). The test is based on peroral administration of a standard dose of methionine and measurement of the plasma homocysteine concentration 4-6 h after intake. The test improved the discrimination of heterozygotes from controls in some studies, but discontinuous segregation between the two groups was not obtained (8). This may reflect the interindividual variation in response to a standard methionine load (9) , which may be due to, among other factors (9), the fact that plasma homocysteine is a function of both homocysteine formation and metabolism.
Homocystine loading has been attempted in patients with homocystinuria, but the results were not interpretable because of the low solubility and absorption of this compound (10) . In another attempt, free base of racemic DL-homocysteine was given to eight homocystinurics and four healthy subjects, and the increase in the free homocysteine mixed and symmetric disulfides was measured in plasma (11).
No data exist on the plasma kinetics of total homocysteine in normal subjects given peroral doses of L-homocysteine. Such data may provide information of homocysteine disposition and metabolism in healthy subjects. In addi-Thirteen healthy volunteers, six women and seven men (ages 19-36 years), participated in the study. The participants had provided their written informed consent, and the protocol was approved by the regional ethical committee of western Norway.
All subjects had plasma concentrations of folate, coba1min, total homocysteine, total cysteine, and methionine within the normal range ( Table 1) .
Homocyst(e)ine Solutions
All homocyst(e)ine solutions were prepared immediately before administration.
Peroral administration.
Reduced One subject (HH) was loaded three times with equal doses (67 mol/kg body weight) of homocysteine, homocystine, and homocysteine thiolactone, to compare the bioavailability of these forms. Blood sampling was performed according to the above protocol.
Another volunteer (BB) was loaded three times with increasing peroral doses (33.5,67, and 134 mol/kg body weight) of homocysteine. The protocol was as described above.
Intravenous administration.
Volunteer BB also received homocysteine as an intravenous dose, ujected over a period of 20 s through a 1.4-mm-diameter cannula mounted in the cubital vein. The homocysteine dose was 67 pmoUkg body weight. Blood samples were collected from the 1.7-mm cannula in the cubital vein of 
where C is the plasma concentration at time t, C0 the extrapolated plasma concentration at t = 0, and k the rate constant of the elimination.
To calculate the absorption rate constant, ka, we used these modifications of the above equations (16):
where C' is the extrapolated plasma concentration at times t during the absorption and distribution phase, R is the residual value, and R0 is the residual value at t = 0.
AUC.,.
is the area under the plasma concentrationtime curve from zero to infinite time, as measured by the trapezoidal rule. Because plasma homocysteine re-
turned to the basal level (<2.5 pmol/L different from the pretreatment level) within 48 h in all subjects receiving the standard dose, AUC0 h was taken as identical to AUC0.
When homocysteine was administered intravenously, the elimination curve showed multiple-compartment characteristics.
Therefore, the volume of distribution (Vd) was calculated as a model-independent parameter (17) :
where D is dose, and AUMCO.. is the area under the curve of product of time and plasma concentration from zero to infinite time.
Clearance (Cl) is calculated according to the equation
Statistical Methods
The results are given as mean and SD. Paired values were compared by using the Wilcoxon signed rank test. Unpaired values were evaluated by the Mann-Whitney U-test. Correlation was tested by using the Spearman rank correlation coefficient (18). Significance levels were always expressed as two-tailed.
Results
In the present work, 13 volunteers received a total of 30 peroral homocysteine loadings. 
None
). The bioavailability (F), obtained by dividing the AUC h obtained after peroral adminis
Kinetics at Different Peroral Doses
To test whether the kinetics were dependent on the loading dose, we gave one person (BB) increasing doses of homocysteine (33.5, 67, and 134 moIJkg)
perorally. There was a linear increase in AUC8 h with dose ( Figure 3) . Clearance (assuming a value for F of 0.53) was 63, 80, and 75 mL'min, and t was 209, 199, and 217 mi respectively. These data show that homocysteine given perorally obeys dose-independent linear kinetics within the dose range investigated.
Interrelations and Statistics of Kinetic Parameters
A standard homocysteine dose (67 molJkg) was given perorally to 13 subjects, and the loading was repeated in 10 of these subjects. The time interval between the two loading experiments was 2-8 weeks. The mean plasma concentration curves for the first and second loadings are shown in Figure 4 , and the corresponding kinetic parameters for each individual in Table 2 .
There was no significant difference between the kinetic parameters obtained for the first and second loadings. There was a rapid absorption phase for the two loadings, corresponding to t,,, of 59 ± 20 and 54 ± 13 and neither parameter was correlated to the fasting basal concentration of homocysteine (data not shown).
Metabolic Effects
The transient hyperhomocysteinemia after homocys- Table 2 ). The cysteine response may at least partly be explained by displacement of cysteine from plasma protein(s) (19).
2880
Plasma methiomne increased within 15 mm after peroral homocysteine swiministration; after 60 mm, the Figure 6 ). The mean increase in plasma homocysteine was -60 mo1/L at this time point. The subjects were allowed to eat after 60 min, which may have influenced the plasma metbionine concentration in samples collected after this time.
The increase in plasma methionmne showed no correlation to preload concentrations of homocysteine or methionine. It was also unrelated to ti,2 or C for increases in plasma homocysteine. There was a significant (P <0.05) positive correlation between AUC h and increase in plasma methionine in the interval 15-90 mm (data not shown).
We investigated the methiomne response in the subject (BB) who received three different doses of peroral homocysteine. The methionine concentration increased as a function of the homocysteine dose (Figure 7 ). When the same subject received intravenous homocysteine, a methionine response was observed 2.5 mm after in.jection, and the methionine concentration increased to a somewhat higher amount (C, = 27.4 pmoI/L, t = 75 mm; data not shown) than observed after peroral administration of the same dose (Figure 7) . Both after the peroral and the intravenous homocysteine loads, we observed no change in S-adenosylhomocysteine concentration in plasma (data not shown).
Urinary Excretion of Homocysteine and Cysteine
In one person (HH), the urine fractions were collected before and for 48 h after a peroral load of homocysteine. . The urinary excretion of homocysteine was proportional to the plasma homocysteine concentration (Figure 8 ), but only 1.9% of the administered dose was excreted unchanged in the urine. The amount of cysteine excreted in the urine did not change to any significant extent after homocysteine loading (data not shown).
DIscussion

HomocysteineForm and Dose
Reduced homocysteine is rapidly (Figure 1 ) and efficiently absorbed from the gastrointestinal tract, and shares this property with homocysteine thiolactone. Homocystine is insoluble in water, and is slowly absorbed when administered as a suspension in water. This is in accordance with the observation of Brenton et the assumption that homocysteine is distributed in total body water (about 60% of total body weight). We wanted to obtain a maximum increase of 100 mol/L in plasma homocysteine. With rapid absorption and a 100% bioavailability of the administered dose, the calculated amount of homocysteine is about 60 pmoI/kg body weight, equivalent to 9 mg of L-homocysteine thiolactone per kilogram of body weight. This was for simplicity increased to 10 mg'kg body weight.
Disposition and Kinetics of Plasma Homocysteine
The kinetic data we obtained provide new information on the disposition of homocysteine during transient Thus, the elimination rate constant may be a measure of the activity of homocysteine-metabolizing enzyme(s). Dose-independent, first-order kinetics (Figures 2-4, 8 Homocysteine is metabolized to cysteine via the transsulfuration pathway (1), but the increased plasma homocysteine was associated with a decline in plasma cysteine ( Figure 6 ) and no increase in urinary cysteine excretion was observed. This may be explained by displacement of cysteine from its binding sites in plasma, as has previously been suggested for other conditions associated with hyperhomocysteinexnma (19,22,23) .
Homocysteine Loadingvs Methionine Loading
In a standard methionine loading test, 100 mg/kg (670 mo1/kg) of methionine is administered perorally, i.e., 10 times higher than the homocysteine dose used in the present work. The kinetics of plasma homocysteine after methionine and homocysteine loadings are quite different. After methionine intake, the increase in homocysteine reaches C after 4-8 h, the C is somewhat lower than after homocysteine loading, and the concentration is reduced to 50% after about 12 h (19, 24) .
Recalculation
of published data (19, 24) shows that the AUC values for homocysteine in plasma after methionine loading are of similar magnitude or slightly higher than after homocysteine loading.
The slow kinetics of the homocysteine response after methionine intake may be explained by a continuous formation of homocysteine from methionmne, which occasionally remains markedly high in plasma even after 12 h (19). Similar AUC values after both methionine and homocysteine loadings add support to the conclusion that the capacity of the homocysteine-metabolizing enzymes far exceeds that required to handle a standard homocysteine loading dose. Assuming that most of the administered methionine is directed into the transmethylationltranssulfuration pathway, similar AUC values also suggest that only a small fraction (<10%) of the homocysteine formed from methiomne is equilibrated with plasma homocysteine, or that administered and endogenously formed homocysteine do not have equal distribution properties.
Kinetic Features and Clinical Applicability
Conceivably, the plasma kinetics of homocysteine after peroral homocysteine loading could reflect the activity of homocysteine-met.abolizing enzyme, whereas the homocysteine response after methionine loading 
